This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

EfficacyEfficacyClinical Trials Safety
Safety
Safety ConsiderationsLong Term SafetySafety Contextualisation Digital Guide Patient ProfilesDosingValue Support & Resources Support & Resources Patient Resources Videos
Materials Contact us

  

Click here for ▼Cibinqo® (abrocitinib) Prescribing Information

 
Updated Safety Recommendation - Abrocitinib should only be used if no suitable treatment alternatives are available in patients: 65 years of age and older, patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), patients with malignancy risk factors (e.g. current malignancy or a history of malignancy). (Cibinqo Summary of Product Characteristics)

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. (Cibinqo Summary of Product Characteristics)
  

Explore how CIBINQO could support Atopic Dermatitis Pathway optimisation and value-based care
 Unlock Value-Based Care in Dermatology


Partner with Pfizer to support pathway change and improve dermatology service delivery

Optimise Prescribing for Better Patient Outcomes

Have local guidelines been reviewed to reflect latest patient outcomes data and improve consistency in care delivery?

Explore resources to support cost-effective prescribing in AD

Let’s talk: Connect with your local Pfizer representative to explore how Cibinqo can support your dermatology service goals. 
  

Request a MeetingLoading
Access the Budget Impact Tool
      
Use this tool to explore the potential financial impact of treatment options for moderate-to-severe Atopic Dermatitis. It’s designed to support clinical and non-clinical decision-makers in evaluating cost-effective prescribing strategies.

To view the tool:
1. Log in to your PfizerPro account.
2. If you’re not registered, follow the simple steps to create an account:
- Enter your professional details.
- Select your therapy areas of interest.
- Set your password and verify your email.
Once registered, you’ll be able to access the Budget Impact Tool directly.
  
 Explore the Budget Impact Tool  Now
Loading
Explore moreEfficacy 
Learn more about the efficacy of Cibinqo
Clinical Trials Overview Loading
Safety 
Read more about the safety profile of Cibinqo
Loading Safety Considerations
    *Superior itch relief was achieved at Week 2 with CIBINQO 200 mg vs dupilumab1
    *Superior skin clearance (EASI-90) with CIBINQO200 mg vs dupilumab at Week 4 and Week 161 
    **Followed up long-term safety profile (up to ~4.5 years) in 3848 patients8 
    • This long-term follow-up revealed no new safety signals with CIBINQO8 
    **MACE, VTE and serious infection have been observed with CIBINQO and other systemic therapies8–10
    **No significant safety signals were identified in certain selected AEs (MACE, VTE, malignancy, serious gastrointestinal events, renal events) in patients treated with JAKi and dupilumab, in observational data10
    †Significantly more patients achieved superior and rapid itch relief (PP-NRS 4) with CIBINQO 200 mg vs dupilumab1
    • Itch relief (PP-NRS4) as early as Day 1 after the first dose of CIBINQO 200 mg1
    †CIBINQO maintained long-term efficacy (EASI and PP-NRS) over 2 years2–6
    †Most patients achieved or maintained response after switching to CIBINQO 200 mg from dupilumab7

    ‡Dose adjustment available based on response to treatment and patient characteristics2
    ‡Flat pricing across both doses of CIBINQO    9

    Both doses of CIBINQO helped patients maintain their response11
    • In case of flare, CIBINQO offers flexibility to recapture response to treatment by returning to a 200 mg dose11
    AD=Atopic Dermatitis; EASI=Eczema Area and Severity Index; TCS = Topical corticosteriod; PP-NRS = Peak Pruritus Numerical Rating Scale. QW2 = Week 2
    References:
    1. Reich K, et al. Lancet. 2022;400(10348):273–282.
    2.     CIBINQO Summary of Product Characteristics.
    3.     Pfizer Ltd. Data on File: REF-CIB3946, Cibinqo (abrocitinib) JADE EXTEND (B7451015). 96-week long term efficacy(from week 12 parent study) (PP-NRS4)_as observed_Data cutoff Sep 2021.
    4.     Pfizer Ltd. Data on File: REF-CIB3945, Cibinqo (abrocitinib) JADE EXTEND (B7451015). 96-week long term efficacy(from week 12 parent study) (EASI 75)_as observed_Data cutoff Sep 2021.
    5.     Pfizer Ltd. Data on File: REF-CIB3942, Cibinqo (abrocitinib) JADE EXTEND (B7451015). 112-week long term efficacy(PP-NRS-4, PP-NRS 0/1)_as observed_Data cutoff Sep 2022.
    6.     Pfizer Ltd. Data on File: REF-CIB3939, Cibinqo (abrocitinib) JADE EXTEND (B7451015). 112-week long term efficacy(EASI 75, EASI 90, EASI 100) _as observed_Data cutoff 5 Sep 2022.
    7.     Silverberg JI, et al. Dermatol Ther (Heidlb). 2025;15(2):367–380.
    8.     Simpson EL, et al. Poster presented at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Meeting 2024; 31 May-3 June 2024; Valencia, Spain.
    9.     NICE BNF. Abrocitinib medicinal forms. Available at: https://bnf.nice.org.uk/drugs/abrocitinib/medicinal-forms. Accessed June 2025.
    10.     Tsai SYC, et al. J Allergy Clin Immunol. 2024;154(5):1195–1203.
    11.     Blauvelt A, et al. JAAD. 2022;86(1):104–112.
    PP-CIB-GBR-2175. January 2026

    Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc/product/12874/rmms. Patients treated with Cibinqo should be given the Patient Card.

    Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

    for MHRA Yellow Card in Google Play or Apple App Store

     

    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    PfizerPro Account

    To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

    Sign In or RegisterAccountSign Out

    This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

     

    This website is brought to you by Pfizer Limited, a company registered in England 

    and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

     

    Copyright © 2026 Pfizer Limited. All rights reserved.

     

    VAT registration number GB201048427

    PP-UNP-GBR-13934. January 2026
    For UK Healthcare Professionals*

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-UNP-GBR-13971. December 2025

    YesNo
    You are now leaving PfizerPro​​​​​
    ​
    You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site.

    PP-UNP-GBR-12070. April 2025​​​​​​​
    ​​​​​​​
    You are now leaving PfizerPro

    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

    PP-UNP-GBR-12107. April 2025
    ​​​​​​​